Proteomic dysregulation associated with cerebral amyloid angiopathy
Alzheimer's & Dementia · 2026-10 · 22 (10)
DOI: 10.1002/alz.71901 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 09.10.2026. Verfasst von Sang-Won Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Proteomics, Brain. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, National Research Foundation of Korea, Ministry of Science and ICT, Republic of Korea.
Abstract (Originalsprache)
INTRODUCTION Cerebral amyloid angiopathy (CAA) is characterized by impaired vascular amyloid‐β clearance, distinct from Alzheimer's disease (AD), underscoring the need to clarify its molecular basis for predicting therapy‐related amyloid‐related imaging abnormalities. METHODS We analyzed post‐mortem brain proteomics from Religious Orders Study and Rush Memory and Aging Project (ROS/MAP) and cerebrospinal fluid (CSF) proteomics from Alzheimer's Disease Neuroimaging Initiative (ADNI) to identify CAA‐associated proteins and network modules, delineate their biological processes and cellular origins, and determine their diagnostic performance. RESULTS Proteomics analysis identified 30 proteins as associated with CAA severity, enriched in pathways distinct from AD pathology, with 11 replicated in ADNI. Two CAA‐associated modules were enriched for microglial vesicle transport and astrocytic potassium‐ion homeostasis. Pseudotime analysis demonstrated a molecular trajectory aligned with increasing CAA severity. Three proteins (RCSD1, FRZB, AKAP6) improved CAA classification beyond demographics and APOE ε4. DISCUSSION This integrative proteomics analysis identifies distinct, reproducible molecular signatures of CAA, revealing glia‐mediated pathways and promising biomarkers for CAA detection and therapy‐related risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
- Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Neurology, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Seongnam-si, Gyeonggi-do, Republic of Korea.
- Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
ORCID-Profile: Sang-Won Han, Kwangsik Nho
Förderung
- NIA NIH HHS
- National Research Foundation of Korea
- Ministry of Science and ICT, Republic of Korea
- NLM NIH HHS
- National Institutes of Health
Zitieren
APA
Han, S. W., Park, Y. H., Pyun, J. M., Bice, P. J., Bennett, D. A., Oveisgharan, S., Saykin, A. J., Kim, S., & Nho, K. (2026). Proteomic dysregulation associated with cerebral amyloid angiopathy. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71901
Vancouver
Han SW, Park YH, Pyun JM, Bice PJ, Bennett DA, Oveisgharan S, et al. Proteomic dysregulation associated with cerebral amyloid angiopathy. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71901
BibTeX
@article{Han2026,
author = {Han, Sang-Won and Park, Young Ho and Pyun, Jung-Min and Bice, Paula J and Bennett, David A and Oveisgharan, Shahram and Saykin, Andrew J and Kim, SangYun and Nho, Kwangsik},
title = {Proteomic dysregulation associated with cerebral amyloid angiopathy},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {10},
doi = {10.1002/alz.71901}
}
EUVIMED